Robert Burns
Stock Analyst at HC Wainwright & Co.
(3.16)
# 1,136
Out of 5,122 analysts
476
Total ratings
42.13%
Success rate
2.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Burns
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Buy | $52 | $42.59 | +22.09% | 14 | Feb 3, 2026 | |
| HURA TuHURA Biosciences | Reiterates: Buy | $10 | $0.47 | +2,042.25% | 5 | Feb 3, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $10 → $12 | $5.20 | +130.77% | 6 | Jan 30, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $31 → $32 | $16.79 | +90.59% | 21 | Jan 29, 2026 | |
| CRDF Cardiff Oncology | Reiterates: Buy | $10 | $1.68 | +495.24% | 4 | Jan 28, 2026 | |
| MOLN Molecular Partners AG | Initiates: Buy | $13 | $4.51 | +188.57% | 2 | Jan 27, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $9 → $50 | $7.70 | +549.35% | 3 | Jan 21, 2026 | |
| TLX Telix Pharmaceuticals | Reiterates: Buy | $20 | $7.14 | +180.11% | 4 | Jan 21, 2026 | |
| NUVB Nuvation Bio | Maintains: Buy | $18 → $17 | $5.90 | +188.14% | 18 | Jan 12, 2026 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $26 → $27 | $13.21 | +104.39% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $52 | $37.28 | +39.48% | 16 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $6.36 | +88.68% | 10 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $32 | $23.44 | +36.52% | 23 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $23 | $11.00 | +109.09% | 26 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $136 → $140 | $108.25 | +29.33% | 46 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $73 | $95.97 | -23.93% | 21 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $9 | $1.56 | +476.92% | 15 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.75 | +14.29% | 22 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $1.16 | +331.03% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 | $7.38 | +62.60% | 20 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $5.88 | +19.05% | 1 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.90 | +79.49% | 22 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.55 | +129.01% | 3 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.29 | +118.34% | 17 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $11.88 | +127.27% | 1 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $2.40 | +1,316.67% | 4 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $8.67 | +61.48% | 22 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $40 | $17.02 | +135.02% | 5 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $22.64 | +85.55% | 11 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $10 | $2.52 | +296.83% | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $13 | $8.14 | +59.71% | 8 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $48 | $27.60 | +73.91% | 5 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $12.55 | +3.59% | 12 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.08 | +362.96% | 11 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $1.74 | +359.77% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $5.04 | - | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $200 | $19.54 | +923.54% | 5 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,320 → $240 | $0.98 | +24,305.13% | 2 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $0.52 | +28,635.63% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $6.07 | +81.22% | 1 | Dec 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50,000 → $45,000 | $2.40 | +1,874,900.00% | 7 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $13 | $1.38 | +842.03% | 1 | Jan 7, 2021 |
Exelixis
Feb 3, 2026
Reiterates: Buy
Price Target: $52
Current: $42.59
Upside: +22.09%
TuHURA Biosciences
Feb 3, 2026
Reiterates: Buy
Price Target: $10
Current: $0.47
Upside: +2,042.25%
Perspective Therapeutics
Jan 30, 2026
Maintains: Buy
Price Target: $10 → $12
Current: $5.20
Upside: +130.77%
Nurix Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $31 → $32
Current: $16.79
Upside: +90.59%
Cardiff Oncology
Jan 28, 2026
Reiterates: Buy
Price Target: $10
Current: $1.68
Upside: +495.24%
Molecular Partners AG
Jan 27, 2026
Initiates: Buy
Price Target: $13
Current: $4.51
Upside: +188.57%
Adicet Bio
Jan 21, 2026
Maintains: Buy
Price Target: $9 → $50
Current: $7.70
Upside: +549.35%
Telix Pharmaceuticals
Jan 21, 2026
Reiterates: Buy
Price Target: $20
Current: $7.14
Upside: +180.11%
Nuvation Bio
Jan 12, 2026
Maintains: Buy
Price Target: $18 → $17
Current: $5.90
Upside: +188.14%
Cullinan Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $26 → $27
Current: $13.21
Upside: +104.39%
Jan 6, 2026
Maintains: Buy
Price Target: $50 → $52
Current: $37.28
Upside: +39.48%
Dec 9, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.36
Upside: +88.68%
Nov 18, 2025
Maintains: Buy
Price Target: $26 → $32
Current: $23.44
Upside: +36.52%
Nov 14, 2025
Maintains: Buy
Price Target: $19 → $23
Current: $11.00
Upside: +109.09%
Nov 10, 2025
Maintains: Buy
Price Target: $136 → $140
Current: $108.25
Upside: +29.33%
Nov 6, 2025
Maintains: Buy
Price Target: $72 → $73
Current: $95.97
Upside: -23.93%
Nov 5, 2025
Maintains: Buy
Price Target: $3 → $9
Current: $1.56
Upside: +476.92%
Nov 3, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.75
Upside: +14.29%
Oct 31, 2025
Upgrades: Buy
Price Target: $5
Current: $1.16
Upside: +331.03%
Oct 27, 2025
Upgrades: Buy
Price Target: $12
Current: $7.38
Upside: +62.60%
Oct 20, 2025
Assumes: Buy
Price Target: $7
Current: $5.88
Upside: +19.05%
Oct 16, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.90
Upside: +79.49%
Oct 13, 2025
Upgrades: Buy
Price Target: $15
Current: $6.55
Upside: +129.01%
Sep 23, 2025
Reiterates: Buy
Price Target: $5
Current: $2.29
Upside: +118.34%
Sep 15, 2025
Initiates: Buy
Price Target: $27
Current: $11.88
Upside: +127.27%
Aug 26, 2025
Reiterates: Buy
Price Target: $34
Current: $2.40
Upside: +1,316.67%
Aug 26, 2025
Maintains: Buy
Price Target: $16 → $14
Current: $8.67
Upside: +61.48%
Aug 22, 2025
Maintains: Buy
Price Target: $41 → $40
Current: $17.02
Upside: +135.02%
Aug 12, 2025
Maintains: Buy
Price Target: $40 → $42
Current: $22.64
Upside: +85.55%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $2.52
Upside: +296.83%
Jul 17, 2025
Maintains: Buy
Price Target: $10 → $13
Current: $8.14
Upside: +59.71%
Jul 2, 2025
Maintains: Buy
Price Target: $40 → $48
Current: $27.60
Upside: +73.91%
Apr 14, 2025
Reiterates: Buy
Price Target: $13
Current: $12.55
Upside: +3.59%
Mar 20, 2025
Reiterates: Buy
Price Target: $5
Current: $1.08
Upside: +362.96%
Mar 19, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.74
Upside: +359.77%
Jan 28, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.04
Upside: -
May 8, 2024
Maintains: Buy
Price Target: $500 → $200
Current: $19.54
Upside: +923.54%
Mar 21, 2024
Maintains: Buy
Price Target: $1,320 → $240
Current: $0.98
Upside: +24,305.13%
Aug 8, 2023
Reiterates: Buy
Price Target: $150
Current: $0.52
Upside: +28,635.63%
Dec 22, 2021
Maintains: Buy
Price Target: $12 → $11
Current: $6.07
Upside: +81.22%
Nov 24, 2021
Maintains: Buy
Price Target: $50,000 → $45,000
Current: $2.40
Upside: +1,874,900.00%
Jan 7, 2021
Maintains: Buy
Price Target: $19 → $13
Current: $1.38
Upside: +842.03%